Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

User Fee Conference Cmte. Could Be Relatively Messy After Clean Floor Votes

Executive Summary

House and Senate avoided some contentious issues when passing their user fee bills, leaving them to an informal conference committee to work out, ideally before the end of June.

You may also be interested in...



FDA Strikes Pragmatic Tone Before Hydrocodone Abuse Prevention Meeting

The agency is convening the Drug Safety and Risk Management Advisory Committee Oct. 29-30 to discuss whether combination hydrocodone products should face further restrictions.

Clinical Trials Not Required For Lidoderm Generics, FDA Tells Endo

The agency distinguishes the lidocaine pain patch from topical dermatological drugs intended to treat skin diseases in rejecting Endo’s call that ANDA sponsors demonstrate bioequivalence through clinical trials, rather than merely pharmacokinetic studies.

Sen. Burr Tries To Pull FDASIA Over For Speeding As Senate Sends Bill To White House

The North Carolina Republican spends more than two hours talking about the user fee bill and other issues in an apparent effort to delay a final vote, but the Senate easily passes it.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel